News Releases
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, Canada, August 27, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates
Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024 Protocol being amended to enhance enrollment and lessen burden on participants in
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference
Vancouver, Canada, August 6, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of
NervGen Pharma Grants Stock Options
Vancouver, Canada. August 2, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the
NervGen Pharma Appoints Neil Klompas to Board of Directors
Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGen Leadership appointment supports the company’s mission to advance NVG-291 after the completion
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, Canada June 25, 2024
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
Vancouver, Canada, June 20, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of
NervGen Pharma Grants Stock Options
Vancouver, Canada. June 6, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Glenn Ives appointed as Chair of the Board John Ruffolo appointed as Chair of the Audit
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
Vancouver, Canada, May 17, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance
NervGen Files Management Information Circular and Announces Board of Directors Transition
Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen’s Board of Directors Annual General Meeting of Shareholders to
NervGen Engages Russo Partners LLC to Provide Public Relations Services
Vancouver, Canada, April 25, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March
NervGen Completes $23 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Vancouver, British Columbia March 28, 2024 – NervGen